Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 2.68 is 134% above its 5-year average of -7.90, near the high end of its 5-year range (-14.55–2.68).
294.39% above its 12-month average of -1.38.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.08.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:51:26.843Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
2.68
EARNINGS PER SHARE (EPS) AVG TTM
-1.38
EARNINGS PER SHARE (EPS) AVG 3Y
-6.44
EARNINGS PER SHARE (EPS) AVG 5Y
-7.90
EARNINGS PER SHARE (EPS) AVG 10Y
-13.70
EARNINGS PER SHARE (EPS) AVG 15Y
-12.69
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+294.39%
CURRENT VS 3Y AVG
+141.59%
CURRENT VS 5Y AVG
+133.94%
CURRENT VS 10Y AVG
+119.56%
CURRENT VS 15Y AVG
+121.13%
CURRENT VS 20Y AVG
N/A
Fortress Biotech, Inc.
Market Cap
$143.67M
Earnings Per Share (EPS)
2.68
TTM Avg
-1.38
3Y Avg
-6.44
5Y Avg
-7.90
Market Cap
$143.10M
Earnings Per Share (EPS)
-2.52
TTM Avg
-2.32
3Y Avg
-1.91
5Y Avg
-1.63
Market Cap
$143.10M
Earnings Per Share (EPS)
-1.36
TTM Avg
-1.75
3Y Avg
-3.23
5Y Avg
-3.64
Market Cap
$145.90M
Earnings Per Share (EPS)
-1.64
TTM Avg
-1.85
3Y Avg
-1.46
5Y Avg
-1.46
Market Cap
$141.00M
Earnings Per Share (EPS)
-17.42
TTM Avg
-26.05
3Y Avg
-23.35
5Y Avg
-21.03
Market Cap
$140.49M
Earnings Per Share (EPS)
-1.04
TTM Avg
-1.66
3Y Avg
-1.77
5Y Avg
-1.60
Market Cap
$147.81M
Earnings Per Share (EPS)
-0.26
TTM Avg
-0.53
3Y Avg
-0.57
5Y Avg
-0.55
Market Cap
$147.95M
Earnings Per Share (EPS)
-0.61
TTM Avg
-0.35
3Y Avg
-0.32
5Y Avg
-0.30
Market Cap
$148.48M
Earnings Per Share (EPS)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fortress Biotech, Inc. (FBIOP) | $143.67M | 2.68 | -1.38 | -6.44 | -7.90 |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -2.52 | -2.32 | -1.91 | -1.63 |
| Protara Therapeutics, Inc. (TARA)vs › | $143.10M | -1.36 | -1.75 | -3.23 | -3.64 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $145.90M | -1.64 | -1.85 | -1.46 | -1.46 |
| Sutro Biopharma, Inc. (STRO)vs › | $141.00M | -17.42 | -26.05 | -23.35 | -21.03 |
| Immuneering Corporation (IMRX)vs › | $140.49M | -1.04 | -1.66 | -1.77 | -1.60 |
| Anavex Life Sciences Corp. (AVXL)vs › | $147.81M | -0.26 | -0.53 | -0.57 | -0.55 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.95M | -0.61 | -0.35 | -0.32 | -0.30 |
| Veraxa Biotech Holding AG (VRXA)vs › | $148.48M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $148.61M | -0.34 | -0.70 | -0.76 | -0.63 |
Trailing EPS (TTM)
$2.68
Forward EPS (Est.)
$2.55
P/E Ratio
6.8
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.07 |
| 2024-12-31 | -2.69 |
| 2023-12-31 | -8.47 |
| 2022-12-31 | -14.55 |
| 2021-12-31 | -11.85 |
| 2020-12-31 | -9.75 |
| 2019-12-31 | -10.95 |
| 2018-12-31 | -29.04 |
| 2017-12-31 | -24.08 |
| 2016-12-31 | -20.68 |
| 2015-12-31 | -18.56 |
| 2014-12-31 | -8.42 |
| 2013-12-31 | -18.32 |
| 2012-12-31 | -19.12 |
| 2011-12-31 | -4.74 |
| 2010-12-31 | -1.69 |
| 2009-12-31 | -15.15 |
| 2008-12-31 | -20.85 |
